Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
ENDP Hot Sheet
EPS Growth %: -13.0%Financial Fact:
Total consolidated income before income tax: -113.85M
Today's EPS Names:
DATE, MLAB, ZLC, More
Endo Pharmaceuticals (NASDAQ: ENDP) reports Q3 EPS of $0.63, versus the analyst estimate of $0.64. Revenue for the quarter was $361.03 million, which compares to the estimate of $365.33 million.
Raises FY09 Guidance to $1.44 - $1.465 billion., and FY09 adjusted EPS expected to be $2.67 - $2.73.
Raises FY09 Guidance to $1.44 - $1.465 billion., and FY09 adjusted EPS expected to be $2.67 - $2.73.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- LTX-Credence Corp (LTXC) Tops Q3 EPS by 3c; Guides Q4 Above Views
- PVH Corp. (PVH) Tops Q1 EPS by 4c; Guides FY12 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
